Recent Updates
Recently added Catalysts
DRTS Positive Sentiment Score: 70/100

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Key Takeaway: Alpha Tau Medical Ltd. (Nasdaq: DRTS) has announced that its CFO, Raphi Levy, will present at the Sidoti Virtual Small Cap Conference, scheduled for March 18-19, 2026. The event will highlight the company's innovative alpha-radiation cancer therapy, Alpha DaRT, which aims to treat solid tumors while sparing surrounding healthy tissue. Attendees will have the opportunity to schedule one-on-one investor meetings with Mr. Levy, further facilitating discussions about the company's developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alpha Tau Medical is actively participating in the Sidoti Virtual Small Cap Conference.
  • The company is presenting its innovative alpha-radiation cancer therapy, Alpha DaRT.
  • The conference provides a platform for potential investor meetings.

Full Press Release Details

JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.
Event: Sidoti Virtual Small Cap Conference
Format: Company Presentation
Date: March 18, 2026
Time: 10:00 – 10:30AM ET
Location: Virtual
Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:

Tags

Frequently Asked Questions

What is Alpha DaRT®?

Alpha DaRT® is an innovative cancer therapy using alpha-radiation for solid tumors.

When will the Sidoti Conference take place?

The Sidoti Virtual Small Cap Conference is on March 18-19, 2026.

Who is presenting at the upcoming conference?

CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference.

What is the focus of Alpha Tau Medical Ltd.?

Alpha Tau Medical focuses on developing and commercializing Alpha DaRT for solid tumors.

How does Alpha DaRT work?

Alpha DaRT delivers radium-224 to tumors, emitting alpha particles to destroy cancer cells.

Last updated: Mar 16, 2026